Ligand id: 6974

Name: romiplostim

No information available.
Summary of Clinical Use
Romiplostim is used to increase the platelet count in patients suffering from chronic idiopathic thrombocytopenic purpura (ITP), a disease characterised by autoimmune destruction of platelets. As of December 2018 the FDA permits use of romiplostim in pediatric ITP patients ≥1 year of age.
Mechanism Of Action and Pharmacodynamic Effects
Romiplostim acts by a similar mechanism to thrombopoietin, activating intracellular transcriptional pathways via the thrombopoietin receptor (the product of the MPL oncogene, c-MPL) which results in increased production and differentiation of megakaryocytes, the platelet precursors. The aim of treatment is to have platelets produced more quickly than they are destroyed by the patient's own immune system.
External links